TY - JOUR
T1 - Targeting the RB-pathway in cancer therapy
AU - Knudsen, Erik S.
AU - Wang, Jean Y J
PY - 2010/2/15
Y1 - 2010/2/15
N2 - The RB-pathway, consisting of inhibitors and activators of cyclin-dependent kinases, the retinoblastoma tumor suppressor (RB), and the E2F-family of transcription factors, plays critical roles in the regulation of cell cycle progression and cell death. Components of this pathway, particularly p16Ink4a, cyclin D1, and RB, are frequently altered in sporadic human cancers to promote deregulated cellular proliferation. The consistent disruption of the RB-pathway in human cancers raises the possibility of exploiting tumor-specific RB-pathway defects to improve the efficacy of current therapies and to develop new therapeutic strategies. This article discusses how the RB-pathway status impacts the cellular responses to cytotoxic, cytostatic, and hormone therapies, and how the components of the RB-pathway may be directly targeted to treat cancer.
AB - The RB-pathway, consisting of inhibitors and activators of cyclin-dependent kinases, the retinoblastoma tumor suppressor (RB), and the E2F-family of transcription factors, plays critical roles in the regulation of cell cycle progression and cell death. Components of this pathway, particularly p16Ink4a, cyclin D1, and RB, are frequently altered in sporadic human cancers to promote deregulated cellular proliferation. The consistent disruption of the RB-pathway in human cancers raises the possibility of exploiting tumor-specific RB-pathway defects to improve the efficacy of current therapies and to develop new therapeutic strategies. This article discusses how the RB-pathway status impacts the cellular responses to cytotoxic, cytostatic, and hormone therapies, and how the components of the RB-pathway may be directly targeted to treat cancer.
UR - http://www.scopus.com/inward/record.url?scp=76749104377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76749104377&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-09-0787
DO - 10.1158/1078-0432.CCR-09-0787
M3 - Article
C2 - 20145169
AN - SCOPUS:76749104377
SN - 1078-0432
VL - 16
SP - 1094
EP - 1099
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -